07 February 2019
Visiongain has launched a new pharma report Translational Regenerative Medicine Market Forecast 2019-2029: Stem Cell Therapies, Tissue Engineered Products, Gene Therapies.
The high potential earning for companies from products aimed at repairing organs and tissues has led to an increase in the attention given to regenerative medicine research. Regenerative medicine (RM) is viewed as possessing the ability to provide therapeutic products targeted at multiple disease classes, such as cardiovascular, dermatological, and orthopaedic conditions. Developments in stem cell therapies and tissue engineering in particular may catalyse rapid growth in the translational regenerative medicine market over the next decade and beyond.
The lead analyst of the report commented "Regenerative medicine has become an area of competition between many national governments, particularly in Asia-Pacific. Partly, this is due to a desire to demonstrate excellence in national biotechnology industries, especially in emerging markets wanting to show progress in moving towards a knowledge-based economy. Governments are also concerned about obtaining a share in the global healthcare market of the future, when TRM products may be expected to overtake other types of treatment in the field of medicine, delivering both improved clinical outcomes and cost savings."
Leading companies featured in the report include Athersys, Inc., Avita Medical, AxoGen, Inc., MEDIPOST Co., Ltd., NuVasive, Astellas Pharma, Organogenesis Holdings Inc., Osiris Therapeutics, Inc. and others.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.
10 September 2019
The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.
09 September 2019
Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.
05 September 2019
Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.